Laboratoires VIVACY, a leading French manufacturer specialising in injectable medical devices for regenerative aesthetics, announces a strategic partnership with AQPHA Medical, a Dutch company focused on the development of advanced biomaterials. This equity partnership marks an important milestone in VIVACY’s continuous investment in research and innovation in regenerative aesthetics.
This collaboration will focus on the development and application of PTMC-based technology (PolyTrimethylene Carbonate) – a cutting-edge biomaterial that has already demonstrated promising potential in several therapeutic areas, in particular tissue and vascular repair.
What is PTMC Technology?
PTMC (PolyTrimethylene Carbonate) is a biodegradable and biocompatible polymer designed to support and stimulate natural tissue regeneration. Thanks to its unique elasticity, mechanical strength, and soft-tissue compatibility, PTMC enables controlled cellular integration and tissue stimulation, minimising inflammatory reactions. Its adaptability makes it a promising material platform for future developments in both aesthetic and medical applications.
“AQPHA Medical’s innovative PTMC technology represents a significant step forward in the field of tissue rejuvenation, offering new possibilities for both clinicians and patients. We are proud to support and collaborate with the AQPHA Medical team as they advance this promising platform,” highlighted Stéphane Meunier, CTO of Laboratoires VIVACY.
A Step Forward in Regenerative Innovation
This partnership reinforces VIVACY’s mission to offer physicians and patients the most advanced regenerative solutions, grounded in scientific excellence and safety. By joining forces with AQPHA Medical, VIVACY aims to explore new frontiers in biomaterials science and expand its expertise beyond hyaluronic acid technologies, paving the way for future innovations in skin and tissue regeneration.
“At VIVACY, our mission has always been to push the boundaries of science to deliver meaningful progress for physicians and patients. Collaborating with AQPHA Medical aligns perfectly with VIVACY’s strategic roadmap to lead the transformation of regenerative aesthetics. This investment reinforces our commitment to scientific excellence and supports our ambition to establish ourselves as a pioneering force in regenerative aesthetics, by bring forward new, advanced technologies that set new standards in our field.” stated Jean-Philippe Hecquet, CEO & President of Laboratoires VIVACY.
“VIVACY’s continued global expansion and commitment to elevating the aesthetics field create an exceptional platform for advancing next-generation biopolymers. At AQPHA, our work is rooted in deep material science, and this partnership allows that science to translate into meaningful global impact with greater precision and reach,” said Donato Di Biase, CEO of AQPHA Medical. “Together, we are enhancing today’s aesthetic solutions while shaping new regenerative and therapeutic possibilities that will set the standard for the decade ahead.”
